An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish ...
Oct 11, 2018
0
0
Analysis of male- and female-derived tumor samples revealed differences in prognostic biomarkers, genes that drive cancer, and in regulation of key pathways that may predict responses to treatment, according to results published ...
Oct 2, 2018
0
4
Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according ...
Sep 30, 2018
0
1
A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid ...
Sep 30, 2018
0
1
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp (HFNS), according to data ...
Sep 30, 2018
0
17
Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) were significantly more likely to relapse than pediatric ALL patients, and factors including lower clinical trial enrollment and shorter duration ...
Sep 27, 2018
0
1
Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls.
Sep 14, 2018
0
0
The American Association for Cancer Research (AACR) today released its annual Cancer Progress Report highlighting how federally funded research discoveries are fueling the development of new and even more effective ways to ...
Sep 12, 2018
0
1
Among a small cohort of patients with HIV-associated Kaposi's sarcoma treated with immune checkpoint inhibitors, more than 65 percent had partial or complete remission.
Sep 7, 2018
0
6
An evolutionary model utilizing serial blood samples from patients with advanced colorectal cancer treated with anti-EGFR therapies in a phase II trial could predict personalized waiting time for progression.
Aug 30, 2018
0
1
